BioCentury
ARTICLE | Company News

Zhejiang Wansheng Pharmaceutical, 3SBio deal

August 3, 2015 7:00 AM UTC

3SBio will acquire Zhejiang Wansheng for RMB528 million ($85.1 million) in cash. Zhejiang Wansheng markets cancer, diabetes and hypertension products in China and had net sales of RMB279.4 million ($45 million) in 2014. 3SBio, which had 2014 sales of RMB1.1 billion ($182.2 million), said the acquisition would allow the company to expand into diabetes and dermatology markets. ...